News Releases

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

With CAR T cell therapy, a patient’s own immune cells are genetically modified and inserted back into the body to find and kill cancer. This form of immunotherapy has already revolutionized some cancer treatments, but once the CAR T cells are inside a patient, where do they go? How do doctors know that they have successfully reached their target and that they are continuing to fight disease weeks, months, or even years later?

Knowing which T cells will lose the battle against cancer earlier could inform treatments and the development of new immunotherapies